Sanara Expects Q4 2025 Net Revenue of $27.2M to $27.7M
Net revenue for the fourth quarter of 2025 is expected to be in the range of $27.2 million to $27.7 million, an increase of approximately 3% to 5%, compared to $26.3 million in the fourth quarter of 2024. "Our team delivered strong performance in 2025, culminating in preliminary net revenue of approximately $103 million, an increase of approximately 19% year-over-year," stated Seth Yon, Sanara's President and Chief Executive Officer. "In the fourth quarter of 2025, our preliminary net revenue increased in the range of 11% to 13% year-over-year, excluding approximately $1.8 million of BIASURGE sales in the prior year period, consistent with the range of expectations shared on our Q3 earnings call. Operationally, we made important progress across multiple areas during the fourth quarter. Importantly, we secured a new contract with Vizient, Inc. - the largest group purchasing organization in the U.S. - which significantly expands access to BIASURGE at contracted pricing and pre-negotiated terms. In addition, we enhanced our sales and distribution network, while also working to expand our product portfolio through our initiatives with BMI related to OsStic."
Trade with 70% Backtested Accuracy
Analyst Views on SMTI
About SMTI
About the author

- Significant Revenue Growth: Sanara MedTech achieved a record $103.1 million in net revenue for 2025, marking a 19% year-over-year increase, which underscores the strength of its hybrid commercial model and is expected to further enhance market share.
- Distributor Network Expansion: The company expanded its network to over 450 independent distributor partners by year-end 2025, up from more than 350 in 2024, successfully penetrating over 1,450 healthcare facilities, thereby increasing market penetration and customer base.
- Strategic Focus Transformation: The completion of the wind-down of the Tissue Health Plus (THP) segment allows the company to concentrate on the surgical market, with core products like CellerateRx Surgical and BIASURGE, which are expected to lay a solid foundation for future growth.
- Optimistic Future Outlook: Management reaffirmed full-year 2026 net revenue guidance between $116 million and $121 million, representing a growth of 13% to 17%, and plans to invest in expanding the sales team and R&D to support sustainable growth.
- Earnings Highlights: Sanara MedTech reported a Q4 GAAP EPS of -$0.19, yet achieved revenue of $27.5 million, reflecting a 4.6% year-over-year growth, demonstrating the company's resilience in challenging conditions.
- Future Outlook: The company anticipates full-year 2026 net revenue to range from $116 million to $121 million, representing a growth of approximately 13% to 17% compared to $103.1 million in 2025, indicating management's confidence in future growth.
- Revenue Expectations: Sanara MedTech expects Q4 revenue to be between $27.2 million and $27.7 million, aligning with actual revenue figures, which reflects the company's stable performance in the market.
- Market Reaction: Despite challenges, Sanara MedTech's financial performance and future guidance may attract investor interest, potentially supporting its stock price performance to some extent.

- Revenue Guidance: Sanara MedTech has provided revenue guidance for FY 2026, estimating between $116 million and $121 million.
- Growth Projection: The company anticipates a growth rate of 13% to 17% for the upcoming fiscal year.
- Revenue Growth: Sanara MedTech's revenue for Q4 2025 has increased by 5%, reaching $27.5 million.
- Financial Performance: The increase in revenue indicates a positive trend in the company's financial performance during this period.
- Earnings Announcement: Sanara MedTech is set to release its fourth quarter and full year 2025 financial results on March 24, 2026, before U.S. markets open, which is expected to provide critical performance data and future outlook for investors.
- Conference Call Details: The company will host a conference call at 8:00 a.m. Eastern Time on the same day to discuss the financial results and hold a Q&A session, likely attracting significant attention from analysts and investors, thereby enhancing market transparency.
- Replay Service Availability: A telephonic replay of the conference call will be available until April 7, 2026, ensuring that investors who cannot participate live can still access the information, thus improving information accessibility.
- Market Positioning: Sanara focuses on developing and commercializing innovative technologies in the surgical market aimed at achieving better clinical outcomes and reducing healthcare expenditures, highlighting its strategic importance in the North American surgical tissue repair market.






